Allschwil, Switzerland, April 4, 2019
Polyphor to present data on murepavadin and its lead preclinical compound of its novel class of Gram-negative antibiotics at the 29th European Congress of Clinical Microbiology and Infectious Diseases
Polyphor AG (SIX: POLN) today announced that 5 abstracts featuring data on its Outer Membrane Targeting Antibiotics (OMPTA), including both its lead product candidate murepavadin (POL7080) and its new medium-spectrum anti Gram-negative lead preclinical compound (POL7306), will be presented at the 29th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) taking place in Amsterdam, Netherlands, from April 13 to16, 2019.
The following abstracts will be presented during the Session PS104, "New membrane-active antibiotics", on April 15, 13:30 - 14:30 h:
Title: Activity of murepavadin against colistin-resistant Pseudomonas aeruginosa clinical isolates
Title: Antimicrobial Activity of POL7306 Tested against Clinical Isolates of Gram-Negative Bacteria Collected Worldwide
Title: Outer membrane protein targeting antibiotics (OMPTAs): PK and in vivo efficacy of POL7306
Title: In vitro propensity of resistance development of POL7306, a new outer membrane protein targeting antibiotic (OMPTA)
Title: POL7306, a new outer membrane protein targeting antibiotic (OMPTA): Effect of testing parameter variations and body fluids on the in vitro activity.
Full abstracts will be available on the ECCMID website: http://www.eccmidlive.org/#
For further information please contact:
Chief Financial Officer
Tel: +41 61 567 16 67
Email: [email protected]
Dynamics Group AG
Tel: +41 43 268 32 31
Email: [email protected]
About Murepavadin (POL7080)
Murepavadin is Polyphor's most advanced product candidate and the first OMPTA in clinical development. It is being developed for the treatment of nosocomial pneumonia (including both hospital-acquired (HABP) and ventilator-associated bacterial pneumonia (VABP)) due to Pseudomonas aeruginosa and has been granted Qualified Infectious Disease Product (QIDP) and fast track designation from the U.S. Food and Drug Administration (FDA) for the treatment of VABP due to Pseudomonas aeruginosa. Murepavadin is a pathogen specific antibiotic functioning through a novel mechanism of action involving binding to an outer membrane protein of Pseudomonas aeruginosa. In contrast to commonly used broad-spectrum antibiotics, murepavadin is a precision medicine and as such it supports the growing practice known as "antibiotic stewardship" which, among other things, seeks to reduce the excessive use of broad-spectrum products to avoid the buildup of resistance and to preserve the microbiome of the patients. Based on promising Phase II results, Polyphor has agreed on a streamlined development pathway for murepavadin with the FDA and EMA and has started its Phase III clinical program.
Polyphor is a clinical stage, Swiss biopharmaceutical company focused on the discovery and development of antibiotics and immuno-oncology compounds. It has discovered and is developing the OMPTA (Outer Membrane Protein Targeting Antibiotics). The OMPTA are potentially the first new class of antibiotics against Gram-negative bacteria to have reached phase III stage in the last 50 years. The company's lead OMPTA, murepavadin, (POL7080) is in Phase III development against Pseudomonas aeruginosa - recognized as a critical priority 1 pathogen by WHO; in addition, Polyphor is developing a pipeline of further preclinical antibiotics based on its OMPTA platform. In addition, Polyphor is developing an immuno-oncology candidate, balixafortide (POL6326), which is starting a Phase III trial in combination with eribulin in patients with advanced breast cancer, and exploring in parallel its potential for further combinations and indications. Polyphor is based in Allschwil near Basel and is listed on the SIX Swiss Exchange (SIX: POLN). For more information, please visit www.polyphor.com.
This press release contains forward-looking statements which are based on current assumptions and forecasts of the Polyphor management. Known and unknown risks, uncertainties, and other factors could lead to material differences between the forward-looking statements made here and the actual development, in particular Polyphor's results, financial situation, and performance. Readers are cautioned not to put undue reliance on forward-looking statements, which speak only of the date of this communication. Polyphor disclaims any intention or obligation to update and revise any forward-looking statements, whether as a result of new information, future events or otherwise.